Aggressive B-Cell Lymphomas: Clinical Application of New Advances in Community Practice

A series of live interactive workshops featuring expert perspectives on managing patients with aggressive B-cell lymphomas. Live simulcasts of 3 workshops will be available as well as a downloadable slideset treatment summary resource guides and an on-demand webcast covering these important topics.

Share

Program Content

Activities

Aggressive B-Cell Lympomas Slides
Aggressive B-Cell Lymphomas: Clinical Application of New Advances in Community Practice
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 08, 2022

Expires: March 07, 2023

Activities

ADCs for B-Cell Lymphoma
Antibody–Drug Conjugates for B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2022

Expires: March 21, 2023

Bispecific Abs in B-Cell Lymphomas
Bispecific Antibodies in B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2022

Expires: March 21, 2023

BTKi for B-Cell Lymphomas
BTK Inhibitors for B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2022

Expires: March 21, 2023

CAR T-cells for B-Cell Lymphomas
CAR T-cell Therapy in B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2022

Expires: March 21, 2023

IMiDs and ICIs for B-Cell Lymphomas
Immunomodulatory Agents and Immune Checkpoint Inhibitors in B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2022

Expires: March 21, 2023

Ab-Based Tx in B-cell Lymphomas
Antibody-Based Therapies for B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2022

Expires: March 21, 2023

XPO1 Inhibitors for B-Cell Lymphomas
XPO1 and Nuclear Export Inhibitors in B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2022

Expires: March 21, 2023

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech, a member of the Roche Group

Genmab US Inc and AbbVie

Karyopharm Therapeutics

Novartis Pharmaceuticals Corporation